A study of the anti-diabetic agents of camel milk

  • Authors:
    • Ajamaluddin Malik
    • Abdulrahman Al-Senaidy
    • Ewa Skrzypczak-Jankun
    • Jerzy Jankun
  • View Affiliations

  • Published online on: June 29, 2012     https://doi.org/10.3892/ijmm.2012.1051
  • Pages:585-592
Metrics: HTML 0 views | PDF 0 views     Cited By: 0 citations

Abstract

The number of people diagnosed with type 2 diabetes has risen steeply recently exhausting the ability of health care systems to deal with the epidemic. Seventy-five percent of people with diabetes live in low- and middle-income countries. The largest populations of diabetics are in China and India, with many of those people living in extreme poverty. Combined forces of governmental health care, charities and donation of pharmaceutical companies would not be able to cope with the financial demands needed for medicaments and treatments for these people. Therefore, it is worth looking into traditional folk remedies to find if there is any scientific merit to justify their claims for alleviating symptoms of diabetes. There is a traditional belief in the Middle East that regular consumption of camel milk helps in the prevention and control of diabetes. Recently, it has been reported that camel milk can have such properties. Literature review suggests the following possibilities: i) insulin in camel milk possesses special properties that makes absorption into circulation easier than insulin from other sources or cause resistance to proteolysis; ii) camel insulin is encapsulated in nanoparticles (lipid vesicles) that make possible its passage through the stomach and entry into the circulation; iii) some other elements of camel milk make it anti-diabetic. Sequence of camel insulin and its predicted digestion pattern do not suggest differentiability to overcome the mucosal barriers before been degraded and reaching the blood stream. However, we cannot exclude the possibility that insulin in camel milk is present in nanoparticles capable of transporting this hormone into the bloodstream. Although, much more probable is that camel milk contains ‘insulin-like’ small molecule substances that mimic insulin interaction with its receptor.

Introduction

Mature insulin is a protein of 51 residues (21 in A chain and 30 in B chain) produced in specialized beta cell islet of the Langerhans in the pancreas. Insulin binds on transmembrane tyrosine kinase receptor (insulin receptor) present in liver, muscle and cells in the fat tissues and stimulates increase glucose uptake from blood and converts it into glycogen to store in the liver and muscles. Insulin regulates carbohydrate and fat metabolism in the body. Failure to control insulin level leads to diabetes mellitus type 1 or 2. Patients with type 1 and ∼40% of type 2 diabetic patients need insulin to control their blood glucose level. Type 2 diabetes is the most common and results from insulin resistance, a condition in which cells fail to use insulin properly.

The number of people diagnosed with type 2 diabetes has risen steeply in last decades severely exhausting the ability of health care systems to deal with the epidemic. Over 300 million people worldwide have diabetes and this most likely will rise to 500 million within the next 20 years. Seventy-five percent of people with diabetes live in low- and middle-income countries and according to prognostics Africa will experience a largest increase in the next generation. The highest incidence of this disease is in the Arabic Middle East, but the largest populations of diabetics are in China and India, with many of those people living in extreme poverty (15). According to a 2005 World Bank estimate, >40% of the total Indian population falls below the international poverty line defined as an income less than US$1.25 a day (Wikipedia, 2011). Combined forces of governmental health care, charities, and donation of pharmaceutical companies would not be able to cope with the financial demands needed for medicaments and treatments for these people. Therefore it is worth looking into traditional folk remedies to investigate if there is any scientific merit to justify their claims for alleviating symptoms of diabetes.

The traditional belief in the Middle East is that regular consumption of camel milk helps in prevention and control of diabetes, it has also been reported that camel milk can have such properties (68). This is a tempting hypothesis since over a few generations the Arab population has drastically changed its diet including drastic reduction of camel milk consumption. This was accompanied by a robust rise of incidence of diabetes. Two independent groups studied influence of regular consumption of camel milk on diabetes and have reported a substantial reduction in the mean dose of insulin needed to obtain glycemic control (6,8,9) and improvement of fasting blood sugar (227.2±17.7 vs. 98.9±16.2 mg/dl), HbA1c (glucosylated hemoglobin) (9.59±2.05% vs. 7.16±1.84%), serum anti-insulin antibodies (26.20±7.69 vs. 20.92±5.45 μU/ml), urinary albumin excretion (25.17±5.43 vs. 14.54±5.62 mg/dl/24 h), reduction of daily insulin dose (48.1±6.95 vs. 23±4.05 units), and body mass index (18.43±3.59 vs. 24.3±2.95 kg/m2) in randomized human study (9). No mechanism was provided to explain this phenomenon.

In different studies it was found that regular consumption of camel milk for a few months significantly improved the condition of diabetic patients and experimental animals (68,10). Zero prevalence of diabetes in camel milk drinking population and the results of use of camel milk in controlled clinical trials on diabetic humans and animals are highly encouraging to use it as natural therapy for the prevention and treatment of diabetes (68,10,11). Such beneficial effects of camel milk might be due to presence of insulin in the milk or some other substance(s) able to modulate glucose level. It contains higher level of insulin than milk from other animals (12) but to be effective it would have to be absorbed directly in the buccal cavity or completely proteolytically protected during passage through stomach and absorbed in the intestine. Camel milk is unique in the sense that it does not respond to acidic agents like other animal milk, possesses different casein content and much larger lipid micelles (13).

Literature review suggests following possibilities: i) insulin in camel milk possesses special properties that make absorption into circulation easier than insulin from other sources or cause resistance to proteolysis; ii) camel insulin is encapsulated in nanoparticles (lipid vesicles) that make possible its passage through stomach and entry into circulation; iii) some other elements of camel milk make it anti-diabetic.

In this study we are trying to understand the role of insulin in camel milk using bioinformatic tools. Sequence, structure similarity and literature review suggest that camel insulin similar to water buffalo and bovine does not possess any properties that should make it more resistant to proteolysis and easier to be absorbed into the circulation. There is no evidence that cow milk has any anti-diabetic properties albeit it does include insulin at lower level (12). However, it cannot be excluded that insulin if encapsulated in nanoparticles can cross digestive track walls. Lastly it is possible also that camel milk contains unidentified small molecules of ‘insulin-like’ regulatory value or of protease inhibitory properties to prevent proteolysis.

Materials and methods

Insulin sequences from different organisms were obtained from UniProt web search engine (http://www.uniprot.org/). Camel insulin (UniProt id: P01320) was used as a template for sequence in PSI-BLAST. The homologous insulin sequences from animals and plants were selected and subjected to multiple sequence alignment performed by Jalview (http://www.jalview.org/). The Multiple Sequence Alignment was color coded according to conservancy. The amino acid sequences of insulin were used to construct phylogenetic tree using BLOSUM62 from MAFFT Multiple Sequence Alignment (http://www.jalview.org/). The alignment quality of the amino acid sequences is based on BLOSUM62. Conservation among insulin sequences were calculated according to Livingstone and Barton. After multiple sequence alignment, consensus sequence represents the most common residues at a particular position. Quality measures the inverse likelihood of unfavorable mutations in the multiple aligned insulin sequences.

Digestive pattern of different insulin was performed by online software, peptide cutter (http://web.expasy.org/peptide_cutter/). The number of the cut sites for pepsin at pH 1.3 and 2.0, trypsin and chymotrypsin with high and low specificity were recorded.

Protein structure modeling

An internet service I-TASSER server was used for protein structure and function predictions. It allows to automatically generate high-quality predictions of 3D structure based on amino acids sequence (14,15).

Results and Discussion

Proteolysis sites of digestive proteases in different types of insulin of different species

Models of human and camel insulin are essentially the same as predicted by I-TASSER (Fig. 1) (14,15). We hypothesized that camel insulin is protected from digestive enzymes in the stomach and thus absorbed in the intestine. The numbers of calculated cut sites for different types of insulin were the same for camel, human, bovine, goat, buffalo, sheep and pig insulin (Table I). The preferred cut sites for pepsin are Phe, Tyr, Trp and Leu. Trypsin prefers Arg and Lys at P1 while chymotrypsin preferentially cleaves at Trp, Tyr and Phe in position P1 (high specificity) and to a lesser extent at Leu, Met and His (low specificity). Camel insulin differs from human insulin by four mutations and from bovine and buffalo by just one mutation. None of the mutations affect specificity toward digestive enzymes. Therefore, camel insulin should be identical to human, bovine, buffalo, goat, sheep and pig insulin in terms of susceptibility toward proteolysis. Thus, when camel insulin comes in contact with the proteases of digestive track it should be digested like other mammalian insulin unless otherwise protected.

Table I.

Proteolysis sites of digestive proteases in different types of insulin.

Table I.

Proteolysis sites of digestive proteases in different types of insulin.

No. of cleavages
InsulinUniport accession no.Pepsin pH 1.3Pepsin pH >2.0TrypsinChymotrypsin high specificityChymotrypsin low specificity
Human (Homo sapiens)P0130822152715
Camel (Camelus dromedaries)P0132022152715
Bovine (Bos taurus)P0131722152715
Water buffalo (Bubalus bubalis)Q25C7822152715
Domestic goat (Capra hircus)P0131922152715
Elephant (Elephas maximus)P0131822152715
Sheep (Ovis aries)P0131622152715
Whale (Physeter macrocephalus)P6797422152715
Chimpanzee (Pan troglodytes)P3041022152715
Hamster (Cricetidae sp.)Q7M0G122152715
Pig (Sus scrofa)P0131522152715
Rabbit (Oryctolagus cuniculus)P0131122152715
Dog (Canis familiaris)P0132122152715
Cat (Felis catus)P0630622152716
Horse (Equus caballus)P0131022152715
Muscovy duck (Cairina moschata)P6824321142614
Goose (Anser)P6824521142614
Turtle (Trachemys scripta)P6904821142615
Ostrich (Struthio camelus)P6796921142615
Turkey (Meleagris gallopavo)P6796821142615
Alligator (Alligator mississippiensis)P1270320133614
Opossum (Didelphis marsupialis virginiana)P1810922152615
Chinchilla (Chinchilla)Q5BVF621142716
Viscacha (Lagidium viscacia)Q5BVF418113615
Mouse (Mus musculus)E0CXX721142716
Bat (Rhinolophus ferrumequinum)B2KIN722152715
Crab-eating macaque (Macaca fascicularis)P3040622152715
Guinea pig (Cavia porcellus)P0132915103612
Jack-bean (Canavalia ensiformis)Q7M21722152715
Camel’s foot tree (Bauhinia purpurea)721138A22152715
Cowpea (Vigna unguiculata)P8377022152715
Insulin sequences

It is commonly believed that insulin sequences of different types of species are highly conserved (1618). However, as shown in Figs. 2 and 3 some species may differ from human by as many as 18 amino acids (out of 51) in mature form of insulin. Camel insulin is identical to bovine and water buffalo, varying from human in Thr54Ala, Thr97Ala, Ile99Val. There is a contradiction on additional variation in camel insulin sequence at Val26Ala as reported byUniProt (19), while Al-Swailem et al reports only Thr54Ala, Thr97Ala, Ile99Val (20).

According to early studies by Pullen et al a number of conserved surface residues, forming the ‘classical binding surface’, were most likely involved in the insulin receptor binding (Gly90, Gln95, Tyr108, Asn110, Val37, Tyr41, Gly48, Phe49, Phe50, Tyr51) (21). The subset of this binding surface (Asn110, Phe49, Phe50, Tyr51), was later proposed to be essential for negative cooperativityin receptor binding by De Meyts et al (22) and confirmed by Xu et al (23). Two insulin mutations known to cause insulinopathy resulting in mild symptoms similar to diabetes type 2 are in this region (insulin Los Angeles: Phe-49-Ser) (24), (insulin Chicago: Phe-50-Leu) (25), see Fig. 4. Although insulin is such a small protein itself it forms dimers that further associate into hexamers important for this enzyme stability. The other residues such as Leu42 and Leu102 that are involved in hexamer-forming surfaces, are engaged also in receptor binding (26). In addition to the original surface residues shown to be important in receptor binding, a cluster of residues (Ser101, Leu102, Glu106, His35, Glu38, and Leu42) known as the primary binding surface disrupt binding to receptor if mutated (27,28). It is worth noting that His10 (35 in Fig. 2) is involved in Zn coordination necessary for the hormone activity.

We analyzed the effect of mutations on the specific activity of insulin. Three relevant human insulin mutants are known (B: Val26Ala, Thr54Ala and A: Thr97Ala). Two mutations (B: Val26Ala and Thr54Ala) in the human insulin increase its specific activity by 110 and 102±21%, respectively, while the third mutation (A: Thr97Ala) decreases specific activity to 87±13% (29). Only one residue (Thr98 of A chain) out of three mentioned above interacts with insulin receptor (27). The mutations in the B chain terminals might have an impact on the conformational changes and stability of the hexamer and their conversion into active monomer.

All these amino acids are conserved in camel, water buffalo and bovine insulin. All three types of insulin are quite unique if compared with others that are identical in primates and vary by one or more amino acid in other species. There is no evidence of anti-diabetic properties of water buffalo and cow milk (3032). Literature search on insulin from sheep and goat varying form, Thr54Ala, Thr97Ala, Ile99Val, by additional mutation Ser98Gly do not provide any evidence on anti-diabetic properties. We conclude that the camel insulin itself is most likely not responsible for anti-diabetic properties of camel milk.

Nano particles

Mucosal surfaces are frequent routes for delivering drugs to the body. Unfortunately, drugs such as peptides and proteins are unable to overcome the mucosal barriers and are degraded (by digestive enzymes if delivered orally) before reaching the blood stream. It provokes the question how insulin in the camel milk could be protected in the stomach to reach the target. Possible explanation may be hidden in the uniqueness of camel milk. Camel milk does not easily coagulate at low pH, it has good buffering capacity, has different proportions of caseines and fatty acids and makes larger lipid micelles than observed in milk of other mammals. It may be possible that insulin in the camel milk is encapsulated in the micelles and passes through the stomach to the intestine. For example when compared with the cow’s milk: i) Kappa caseine micellar fraction reacting with clotting enzymes has different electro-potential and lower electrophoretic mobility and accounts for only ∼5% of total casein vs. ∼13.6% in cow, ii) The micellar size show the mean diameter of 280÷325 μm vs. 160 μm for cow (13), iii) Raw cow milk contains less insulin than camel and it loses even more in processing before reaching a diary store (12). There is evidence that size of lipid micelles becomes larger in milk of cows exposed to hot weather and water deprivation (33). In the desert climate camels are well adjusted to both such conditions, which might explain unique properties of their milk even during drought (34). If due to unique features of the camel milk, insulin is able to cross stomach and get absorbed efficiently into blood stream then ‘camel milk-like features’ could be used for the formulation of insulin for oral delivery in humans. We do not have evidence of insulin presence in micelles, although nanoparticles were used for oral delivery of proteins (3537). Nafissi-Varcheh et al investigated biodegradable polyester polymers with different molecular weights and lactic/glycolic acids ratios in simulated gastrointestinal fluids. They intend to use microparticles for oral protein delivery. They reported that nanoparticles could be suitable for the preparation of protein-loaded microspheres (35).

Prego et al used the mucoadhesive polysaccharide chitosan nanoparticles, chitosan-coated oil nanoparticles and chitosan-coated lipid nanoparticles showing significant capacity for the association of proteins such as insulin, salmon calcitonin and other proteins. They showed that chitosan-coated nanoparticles exhibited capacity to enhance the intestinal absorption of the model peptide, salmon calcitonin, and long-lasting decrease in the calcemia levels in animals (36). Vila et al developed new biodegradable polymer nanoparticles: poly(ethylene glycol) (PEG)-coated poly(lactic acid) (PLA) nanoparticles, chitosan (CS)-coated poly(lactic acid-glycolic acid (PLGA) nanoparticles and chitosan (CS) nanoparticles. These were tested successfully to load proteins, and to deliver them in an active form to transport them across intestinal mucosae (37).

Insulin-like small molecules

He et al developed an in vitro screening assay searching for insulin mimetics. Screening the small molecule chemical libraries, they found a compound (5,8-diacetyloxy-2,3-dichloro-1,4-naphthoquinone, Fig. 5a) that activates insulin receptor directly binding to the receptor kinase domain, to trigger its kinase activity sensitizing insulin’s action. Drug was delivered orally to wild-type C57BL/6J mice and db/db (diabetic) and ob/ob (obese) mice and it was shown to elevate glucose uptake in adipocytes (38).

Mozaffarian et al investigated over 3700 adults in the Cardiovascular Health Study to determine if trans-palmitoleate (trans-16:1n-7, Fig. 5b) was related to new-onset diabetes. An endogenous cis-palmitoleic acid (Fig. 5c) (of adipose or hepatic source), could be beneficial protecting against insulin resistance but also harmful causing cardiovascular risk in humans. Contrary, trans-palmitoleic was associated with lower incidence of diabetes. The individuals taking it had a much lower risk of developing diabetes; ∼60% lower risk among participants in the highest quintile (39). Trans-palmitoleate is strictly exogenous and naturally, occurring in dairy/ruminant trans-fats. It is worth noting that among long chain fatty acids present in camel milk C16 and C18 dominate with C16 on par to cow milk in saturated category but ∼3 times higher for unsaturated C16:1 (39). This might further support the anti-diabetic benefits of drinking camel milk. Additionally, substantial work has been carried out in plants, as reviewed below.

Insulin and insulin-like molecules in plants

Traditional holistic practitioners in many different parts of the world recommend the consumption of plants variety for regulation of glycaemia (4046). There are also more systematic approaches to evaluate anti-diabetic activity of food. Broadhurst et al examined the possible effects of 49 herbs, spices, and medicinal plant extracts on the insulin-dependent utilization of glucose using a rat epididymal adipocyte assay. They found that cinnamon was the most bioactive product followed by witch hazel, green and black teas, allspice, bay leaves, nutmeg, cloves, mushrooms, and brewer’s yeast (43). However, no particular active chemicals were identified.

Varieties of legumes were reported to have anti-diabetic properties (4750). Bean pods (Phaseolus vulgaris) are among the most used traditional remedies with anti-diabetic activity. To be effective, fairly high doses of aqueous extracts need to be given. There is no clear evidence what the active ingredient is. However, authors suggest that by α-amylase inhibitory effect, beans might be effective in preventing or ameliorating type 2 diabetes (48). Nevertheless, beans similarly like camel milk contain insulin or insulin-like protein sequences. Soon after discovery of pancreatic insulin in early 1920s, insulin-like protenaceous material was found in many plants (bean, lettuce, onion and beat). In the 1970s and 80s, several research groups have isolated and well characterized insulin-like protenaceous material and found that it exhibits same hypoglycemic activity, identical molecular weight, chromatographic and immunological properties. In 2003, high level (50 mg insulin/100 g protein = ∼1000 units insulin/100 g protein) of insulin-like substance from legume Vigna unguicultata (cowpea) was detected.

Of note, sequence of cowpea insulin-like material was identical to bovine insulin and similar to human insulin (three mutations at Thr54Ala in the B chain and Thr97Ala and Ile99Val in the A chain as shown in Fig. 2) and camel insulin (just one mutation at Val26Ala in the B chain). Presence of insulin in plants is disputed by biologists despite the fact that insulin was proven to be present in beans and beans supplemented with insulin/glucose were able to accelerate Canavalia ensiformis (Jack bean) seedling development (51,52). Additionally, Xavier-FilhoI et al reported that proteins associated with insulin signaling pathways in vertebrates are also present with insulin-like molecules in plants (52). This raises question if consumption of insulin containing beans can alleviate symptoms of diabetes. It seems to be very unlikely due to the fact that most beans are consumed boiled that would denature proteins.

The other possibility is presence of other molecules that can have drug-like properties. For example α-amylase is an enzyme that hydrolyses α-bonds of large polysaccharides, such as starch and glycogen, yielding glucose and maltose (53,54). Inhibitors of α-amylase are oral anti-diabetic drugs that reduce the impact of carbohydrates on blood sugar.

Reducing excessive intake of refined carbohydrates plays an important role in prevention of obesity and type 2 diabetes mellitus. Tormo et al, studied purified pancreatic α-amylase inhibitor from white beans (Phaseolus vulgaris) that was administered orally for 22 days to non-diabetic and type 2 diabetic Wistar rats. α-Amylase inhibitor from that bean significantly reduced glycaemia in the ND and diabetic animals (55). Two other reports strongly support these findings about anti-diabetic effects of α-amylase inhibitors from beans (47,56).

Controlled clinical experiment of camel insulin on diabetic patients showed that regular consumption of camel milk lowered blood glucose level and in 25% of patients additional insulin requirement was reduced. It is contrary to the results of insulin therapy on the diabetic patients. Once insulin therapy starts, patient has to take insulin lifelong and generally insulin dose keeps on increasing with time. It seems that camel milk delivers insulin in a different form (than in other mammals) and/or provides some other compound in addition to insulin that improve the health of diabetic patients.

Sequence of camel insulin and its predicted digestion pattern do not suggest differentiability to overcome the mucosal barriers before been degraded and reaching the blood stream. However we cannot exclude the possibility that insulin in camel milk is present in nanoparticles capable of transporting this hormone into the blood stream. Although, much more probable is that camel milk contains ‘insulin-like’ small molecular substances that mimic insulin interaction with its receptor.

Acknowledgements

This work was supported by grant from Stranahan Endowment Fund for Oncological Research. The authors (A.M. and A.A.-S.) extend their appreciation to the Deanship of Scientific Research at King Saud University for funding the work through the research group project no RGP-VPP-151.

References

1. 

NA Al-BaghliAJ Al-GhamdiKA Al-TurkiAH Al ElqAG El-ZubaierA BahnassyPrevalence of diabetes mellitus and impaired fasting glucose levels in the Eastern Province of Saudi Arabia: results of a screening campaignSingapore Med J51923930201121221496

2. 

KA AlqurashiKS AljabriSA BokhariPrevalence of diabetes mellitus in a Saudi communityAnn Saudi Med311923201110.4103/0256-4947.7577321245594

3. 

Diabetes - a global threatLancet3731735200910.1016/S0140-6736(09)60954-5

4. 

E GinterV SimkoDiabetes type 2 pandemic in 21st centuryBratisl Lek Listy111134137201020437822

5. 

C SetacciG de DonatoF SetacciE ChisciDiabetic patients: epidemiology and global impactJ Cardiovasc Surg50263273200919543188

6. 

RP AgrawalR DograN MohtaR TiwariS SinghalS SultaniaBeneficial effect of camel milk in diabetic nephropathyActa Biomed80131134200919848050

7. 

RP AgrawalS JainS ShahA ChopraV AgarwalEffect of camel milk on glycemic control and insulin requirement in patients with type 1 diabetes: 2-years randomized controlled trialEur J Clin Nutr6510481052201121629270

8. 

RH MohamadZK ZekryHA Al-MehdarCamel milk as an adjuvant therapy for the treatment of type 1 diabetes: verification of a traditional ethnomedical practiceJ Med Food12461465200910.1089/jmf.2008.000919459752

9. 

RP AgrawalR BeniwalDK KocharCamel milk as an adjunct to insulin therapy improves long-term glycemic control and reduction in doses of insulin in patients with type-1 diabetes A 1 year randomized controlled trialDiabetes Res Clin Pract681761772005

10. 

A SbouiT KhorchaniM DjeghamA AgrebiH ElhatmiO BelhadjAnti-diabetic effect of camel milk in alloxan-induced diabetic dogs: a dose-response experimentJ Anim Physiol Anim Nutr94540546201019906135

11. 

OU BegH von Bahr-LindstromZH ZaidiH JornvallA camel milk whey protein rich in half-cystine. Primary structure, assessment of variations, internal repeat patterns, and relationships with neurophysin and other active polypeptidesEur J Biochem159195201198610.1111/j.1432-1033.1986.tb09852.x

12. 

O ZagòrskiA MamanA YafeeA MeislesC van CreveldR YagilInsulin in milk - a comparative studyInt J Anim Sci1324124419983530717

13. 

Food and Agriculture Organization of the United NationsCamel milk and cheese makingThe Technology of Making Cheese from Camel Milk (Camelus dromedarius)FAO Animal Production and Health Paper 113Rome2011

14. 

A RoyA KucukuralY ZhangI-TASSER: a unified platform for automated protein structure and function predictionNat Protoc5725738201010.1038/nprot.2010.520360767

15. 

Y ZhangTemplate-based modeling and free modeling by I-TASSER in CASP7Proteins69Suppl 8108117200710.1002/prot.2170217894355

16. 

GI BellMM StempienNM FongLB RallSequences of liver cDNAs encoding two different mouse insulin-like growth factor I precursorsNucleic Acids Res1478737882198610.1093/nar/14.20.78733774549

17. 

I ShikataY MaeharaT FujiyoshiH EndoIsolation and characterization of a conserved sequence highly expressed in tumors and growing cellsOncology44192198198710.1159/0002264752439968

18. 

CR SnellDG SmythProinsulin: a proposed three-dimensional structureJ Biol Chem250629162951975808541

19. 

WO DanhoThe isolation and characterization of insulin of camel (Camelus dromedarius)J Fac Med Baghdad1416281972

20. 

AM Al-SwailemMB Al-FageehEJ AlyamaniMM ShehataTA Al-ShammariCharacterization of recombinant Arabian camel (Camelus dromedarius) insulinAfr J Biotechnol7338933942008

21. 

RA PullenDG LindsaySP WoodReceptor-binding region of insulinNature259369373197610.1038/259369a0175286

22. 

P De MeytsE Van ObberghenJ RothMapping of the residues responsible for the negative cooperativity of the receptor-binding region of insulinNature2735045091978661960

23. 

J XuV ChangSB JosephPeroxisomal proliferator-activated receptor alpha deficiency diminishes insulin-responsiveness of gluconeogenic/glycolytic/pentose gene expression and substrate cycle fluxEndocrinology14510871095200410.1210/en.2003-1173

24. 

S ShoelsonM FickovaM HanedaIdentification of a mutant human insulin predicted to contain a serine-for-phenylalanine substitutionProc Natl Acad Sci USA8073907394198310.1073/pnas.80.24.73906424111

25. 

DF SteinerHS TagerSJ ChanK NanjoT SankeAH RubensteinLessons learned from molecular biology of insulin-gene mutationsDiabetes Care13600609199010.2337/diacare.13.6.6002192846

26. 

L SchafferA model for insulin binding to the insulin receptorEur J Biochem22111271132199410.1111/j.1432-1033.1994.tb18833.x8181471

27. 

CC YipP OttensmeyerThree-dimensional structural interactions of insulin and its receptorJ Biol Chem2782732927332200310.1074/jbc.R30002120012764141

28. 

AM JorgensenHB OlsenP BalschmidtJJ LedSolution structure of the superactive monomeric des-[Phe(B25)] human insulin mutant: elucidation of the structural basis for the monomerization of des-[Phe(B25)] insulin and the dimerization of native insulinJ Mol Biol25768469919968648633

29. 

C KristensenT KjeldsenFC WibergAlanine scanning mutagenesis of insulinJ Biol Chem2721297812983199710.1074/jbc.272.20.129789148904

30. 

E MedhammarR Wijesinha-BettoniB StadlmayrE NilssonUR CharrondiereB BurlingameComposition of milk from minor dairy animals and buffalo breeds: a biodiversity perspectiveJ Sci Food AgricNov142011(Epub ahead of print)

31. 

VN MichelizziMV DodsonZ PanWater buffalo genome science comes of ageInt J Biol Sci6333349201010.7150/ijbs.6.33320582226

32. 

GP PizzutiGC SalvatoriSome blood parameters of water buffalo in different physiological conditionsBoll Soc Ital Biol Sper6964965419938198807

33. 

J ScherContribution à l’étude de l’influence de la composition des micelles sur la coagulation enzymatique Inst. National Polytech., Vandéuvre-lès-Nancy, 1988 (In French)

34. 

T BekeleN LundeheimK DahlbornMilk production and feeding behavior in the camel (Camelus dromedarius) during 4 watering regimensJ Dairy Sci9413101317201110.3168/jds.2010-365421338796

35. 

N Nafissi-VarchehM ErfanR AboofazeliAn approach to the design of a particulate system for oral protein delivery. I In vitro stability of various poly (alpha-hydroxy acids)-microspheres in simulated gastrointestinal fluidsJ Microencapsul25584592200810.1080/02652040802485485

36. 

C PregoM GarciaD TorresMJ AlonsoTransmucosal macromolecular drug deliveryJ Control Release101151162200510.1016/j.jconrel.2004.07.03015588901

37. 

A VilaA SanchezM TobioP CalvoMJ AlonsoDesign of biodegradable particles for protein deliveryJ Control Release781524200210.1016/S0168-3659(01)00486-211772445

38. 

K HeCB ChanX LiuIdentification of a molecular activator for insulin receptor with potent anti-diabetic effectsJ Biol Chem2863737937388201110.1074/jbc.M111.24738721908618

39. 

D MozaffarianH CaoIB KingTrans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort studyAnn Intern Med153790799201010.7326/0003-4819-153-12-201012210-0000521173413

40. 

KR AbeywickramaWD RatnasooriyaAM AmarakoonOral hypoglycaemic, antihyperglycaemic and antidiabetic activities of Sri Lankan Broken Orange Pekoe Fannings (BOPF) grade black tea (Camellia sinensis L.) in ratsJ Ethnopharmacol135278286201110.1016/j.jep.2011.02.03521397000

41. 

MR ArdalanMK TarzamniMM ShojaBlack tea improves endothelial function in renal transplant recipientsTransplant Proc3911391142200710.1016/j.transproceed.2007.04.01017524915

42. 

N BoonHealth potential for functional green teas?Int J Vitam Nutr Res78275281200810.1024/0300-9831.78.6.27519685436

43. 

CL BroadhurstMM PolanskyRA AndersonInsulin-like biological activity of culinary and medicinal plant aqueous extracts in vitroJ Agric Food Chem48849852200010.1021/jf990451710725162

44. 

A BuyukbalciSN ElDetermination of in vitro antidiabetic effects, antioxidant activities and phenol contents of some herbal teasPlant Foods Hum Nutr632733200810.1007/s11130-007-0065-518183488

45. 

A CrozierIB JaganathMN CliffordDietary phenolics: chemistry, bioavailability and effects on healthNat Prod Rep2610011043200910.1039/b802662a19636448

46. 

PL OwenLC MartineauD CavesPS HaddadT MatainahoT JohnsConsumption of guava (Psidium guajava L) and noni (Morinda citrifolia L) may protect betel quid-chewing Papua New Guineans against diabetesAsia Pac J Clin Nutr176356432008

47. 

DG BlackTM TaylorHJ KerrS PadhiTJ MontvillePM DavidsonDecontamination of fluid milk containing Bacillus spores using commercial household productsJ Food Prot71473478200818389688

48. 

E SkrodenieneD MarciulionyteZ PadaigaE JasinskieneV Sadauskaite-KuehneJ LudvigssonEnvironmental risk factors in prediction of childhood prediabetesMedicina445663200818277090

49. 

HB XuKX HuangYS ZhuHypoglycaemic effect of a novel insulin buccal formulation on rabbitsPharmacol Res46459467200210.1016/S104366180200204912419651

50. 

GG BriggsPJ AmbroseMP NageotteG PadillaHigh-dose carisoprodol during pregnancy and lactationAnn Pharmacother42898901200810.1345/aph.1L04218460586

51. 

O CalderonC PadillaC ChavesL VillalobosML AriasEvaluation of the effect of Lactobacillus rhamnosus probiotic culture added to yogurt over Staphylococcus aureus, Escherichia coli O157:H7, Listeria monocytogenes and Salmonella enteritidis populationsArch Latinoam Nutr5751552007(In Spanish)

52. 

P PadraoN LunetAC SantosH BarrosSmoking, alcohol, and dietary choices: evidence from the Portuguese National Health SurveyBMC Public Health7138200710.1186/1471-2458-7-13817608935

53. 

R PadhiFeedback linearization based computer controlled medication design for automatic treatment of parturient paresis of cowsComput Methods Programs Biomed841926200610.1016/j.cmpb.2006.07.009

54. 

R LoriniL MinicucciF NapoliScreening for type 1 diabetes genetic risk in newborns of continental Italy. Primary prevention (Prevefin Italy) - preliminary dataActa Biomed76Suppl 33135200516915793

55. 

CF GomesEM TrezzaEC MuradeCR PadovaniSurface electromyography of facial muscles during natural and artificial feeding of infantsJ Pediatr82103109200610.2223/JPED.145616614763

56. 

A WaldmannJ KurykinU JaakmaThe effects of ovarian function on estrus synchronization with PGF in dairy cowsTheriogenology6613641374200610.1016/j.theriogenology.2006.04.03016815540

Related Articles

Journal Cover

September 2012
Volume 30 Issue 3

Print ISSN: 1107-3756
Online ISSN:1791-244X

2016 Impact Factor: 2.341
Ranked #21/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Malik, A., Al-Senaidy, A., Skrzypczak-Jankun, E., & Jankun, J. (2012). A study of the anti-diabetic agents of camel milk. International Journal of Molecular Medicine, 30, 585-592. https://doi.org/10.3892/ijmm.2012.1051
MLA
Malik, A., Al-Senaidy, A., Skrzypczak-Jankun, E., Jankun, J."A study of the anti-diabetic agents of camel milk". International Journal of Molecular Medicine 30.3 (2012): 585-592.
Chicago
Malik, A., Al-Senaidy, A., Skrzypczak-Jankun, E., Jankun, J."A study of the anti-diabetic agents of camel milk". International Journal of Molecular Medicine 30, no. 3 (2012): 585-592. https://doi.org/10.3892/ijmm.2012.1051